Tayek et al. [12] previously found that treatment with 5-FU in patients with colorectal cancer significantly increased fasting hepatic glucose production (HGP) and plasma glucose levels, but the insulin response to intravenous glucose challenge remained unchanged. Here, INS is linked to colorectal cancer.